Segura Schmitz Lucia, Hennermann Julia B, Lollert André
Dtsch Med Wochenschr. 2024 Oct;149(21):1263-1269. doi: 10.1055/a-2295-1592. Epub 2024 Oct 9.
Lysosomal storage disorders (LSD) are a heterogenous group of inborn errors of metabolism due to lysosomal malfunction. LSDs affect 1 in 5000 live births, albeit every LSD itself has a low incidence. The most common LSDs are Fabry disease and Gaucher disease. The underlying cause mainly is an enzyme deficiency but may also be due to defects in transport or activation proteins, which result in progressive intra- and extra-lysosomal accumulation of undegraded storage material. The lysosomes play a key role in degradation and cellular recycling of macromolecules. Besides disturbance of cellular function, substrate accumulation may result in secondary toxic and/or inflammatory processes. For treatment of Fabry and Gaucher disease, several therapeutic approaches are approved including enzyme replacement therapy, chaperon therapy for Fabry disease and substrate reduction therapy for Gaucher disease.
溶酶体贮积症(LSD)是一组由于溶酶体功能障碍导致的先天性代谢缺陷疾病。溶酶体贮积症在每5000例活产婴儿中出现1例,尽管每种溶酶体贮积症本身的发病率都很低。最常见的溶酶体贮积症是法布里病和戈谢病。其根本原因主要是酶缺乏,但也可能是由于转运或激活蛋白缺陷,导致未降解的储存物质在溶酶体内外进行性蓄积。溶酶体在大分子的降解和细胞循环中起关键作用。除了细胞功能紊乱外,底物蓄积可能导致继发性毒性和/或炎症过程。对于法布里病和戈谢病的治疗,已批准了几种治疗方法,包括酶替代疗法、法布里病的伴侣疗法和戈谢病的底物减少疗法。